Adagene Inc. (ADAG)
Nasdaq · Healthcare · Biotechnology
$2.80−1.75%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $188M
- 52-week range
- $1.30 – $4.85
- 52-week change
- +43.22%
- EPS (trailing)
- −$0.38
- Analyst rating
- 1.0 Strong buy
Fiscal year to Dec 2025
- Revenue
- $7.7M (+7333.04%)
- Net income
- −$17.6M
- Operating margin
- −279.5%
- Diluted EPS
- −$0.30
- Free cash flow
- −$15.7M
From the company’s annual report on SEC EDGAR.
About Adagene Inc.
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development.
Headquarters: Suzhou, China · 128 employees · adagene.com